Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib

23 Mar 2020

Abstract excerpt

Approximately 5% of patients with NSCLC present ALK gene rearrangements, which define a distinct molecular subgroup of NSCLC.1 Nevertheless, in addition to the classic ALK fusion partner EML4, other emerging ALK fusion partners bring great challenges to the targeted crizotinib therapy in clinics.2 Herein we report a novel ALK fusion partner, the Linc00308/D21S2088E intergenic region, that conferred responsiveness...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32217130
DOI: 10.1016/j.jtho.2020.03.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to CrizotinibPMID 32217130Read ↗

Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patientSemantic proximity Read ↗

Identification of a novel crizotinib-sensitive MET–ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencingSemantic proximity Read ↗

Effective Treatment With Endostar and Crizotinib Sequential Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases Harboring a Novel CLHC1/RNT4 Intergenic Region- ALK FusionSemantic proximity Read ↗

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020Semantic proximity Read ↗

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.Semantic proximity Read ↗

A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasisSemantic proximity Read ↗

Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.Semantic proximity Read ↗

Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with CrizotinibSemantic proximity Read ↗

A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.Semantic proximity Read ↗

Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.Semantic proximity Read ↗

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to CrizotinibSemantic proximity Read ↗

A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.